Receptos MS drug hits primary endpoint in Phase 2 trial

|By:, SA News Editor

Shares of Receptos (RCPT) are up 36% premarket on higher-than-normal volume in response to the company's report on successful Phase 2 results for its selective S1P1 receptor modulator, RPC1063, for relapsing multiple sclerosis. The drug met its primary endpoint of reducing the cumulative number of gadolinium-enhancing ((GdE)) lesions determined by MRI from week 12 to week 24 of treatment. Patients on RPC1063 experienced a statistically significant reduction in GdE lesions of 86% versus placebo.

Patient recruitment for a Phase 3 trial is underway.